Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NRC-2694-A + paclitaxel
- Development stage
- Phase 2
- Lead developer
- NATCO Pharma
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
NRC-2694-A + paclitaxel is an investigational combination therapy consisting of NRC-2694-A—a small molecule, orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor—and paclitaxel, an established microtubule inhibitor chemotherapeutic. NRC-2694-A is designed to block EGFR-mediated signaling, which plays a key role in tumor proliferation and survival, particularly in squamous cell cancers. Paclitaxel disrupts cell division by stabilizing microtubules, resulting in apoptosis. This combination is being developed for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed on or after immune checkpoint inhibitor therapy. NRC-2694-A is being developed and tested by Natco Pharma.
02
Targets
TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on NRC-2694-A + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRC-2694-A + paclitaxel.